Home > Press > ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center
Abstract:
Harris & Harris Group, Inc. (NASDAQ:TINY), an investor in transformative companies enabled by disruptive science, wanted to let you know that its portfolio company, ORIG3N, Inc., will join three of its other portfolio companies, D-Wave Systems, Inc., HZO. Inc., and Metabolon, Inc. in the morning of presentations on Tuesday, June 7, 2016, at the New York Genome Center, 101 Ave of the Americas, New York, NY 10013, from 8:30 a.m. to 12:00 p.m. ET. These presentations will be followed by Harris & Harris Group's Annual Meeting of Shareholders which the Board of Directors has set for the same day, June 7, 2016, beginning at 12:00 p.m. ET.
In addition to a brief presentation, ORIG3N will be collecting blood from willing volunteers to add to its LifeCapsule repository, which is the world's largest blood cell repository dedicated to supporting regenerative medicine. In addition, the company will be offering its LifeProfile tests, which are a series of genetic tests that show how your genes impact specific areas of lifestyle including fitness potential and insights about skin.
If you are interested in attending, and have not already registered, please register at https://hhvc.regfox.com/june2016event.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com and on Facebook at www.facebook.com/harrisharrisvc.
####
About Harris & Harris Group
Harris & Harris Group is a publicly traded, internally managed business development company that builds transformative companies from disruptive science. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com, on Facebook at www.facebook.com/harrisharrisvc and by following on Twitter @harrisandharrisgroup.
About ORIG3N, Inc.
ORIG3N is a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and rapidly delivering the resulting data to inform therapeutic decisions, ORIG3N will replace trial and error guess work of treating disease and enable longer, healthier lives. The founders are serial entrepreneurs who's previous venture, ArtusLabs, was acquired by PerkinElmer in 2011. For more information, visit: www.orig3n.com.
About D-Wave Systems, Inc.
D-Wave Systems is a quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing and computer science into breakthrough approaches to computation to help solve some of the world's most complex challenges. The company's quantum computers are built using a novel type of superconducting processor that uses quantum mechanics to massively accelerate computation. D-Wave's customers include some of the world's most prominent organizations including Lockheed Martin and Google, whose system is hosted at NASA's Ames Research Center. With headquarters near Vancouver, Canada, D-Wave U.S. is based in Palo Alto, California. D-Wave has a blue-chip investor base including Bezos Expeditions, BDC Capital, DFJ, Goldman Sachs, Growthworks, Harris & Harris Group, In-Q-Tel, International Investment and Underwriting, and Kensington Partners Limited. For more information, visit: www.dwavesys.com.
About HZO, Inc.
HZO is a technology solutions and licensing company that protects electronics from damage caused by liquid submersion, corrosive environments, humidity, sweat, dust and debris. The company provides a powerful thin-film technology for electronics' manufacturers and device makers in sectors ranging from consumer and automotive to LEDs and industrial. With an emphasis on building its patent portfolio and over 150 unique product validations, HZO enables product design freedom and creates product differentiation by performing reliably well beyond defined electronics testing standards like IPX7. With scalable end-to-end solutions that support mass volume production, and a world-class technical team dedicated to innovation and customer success, HZO works with top brands like Motorola, Dell, Nike and Deutsche Telekom to deliver electronics that can be used in all conditions and environments. For more information and contact info, visit http://www.hzo.com.
About Metabolon, Inc.
Metabolon is a health technology company focused on metabolomics - a powerful tool for assessing health. Its proprietary platforms and informatics are delivering biomarker discoveries, innovative diagnostic tests, breakthroughs in precision medicine, and ground-breaking partnerships in genomics-based health initiatives. Metabolon's expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 4,000 independent and collaborative studies, resulting in over 500 peer-reviewed publications. For more information, please visit www.metabolon.com.
Additional Information Regarding Annual Meeting Solicitation
The Company filed a definitive proxy statement and related materials with the Securities and Exchange Commission ("SEC") in connection with its 2016 Annual Meeting of Shareholders (the "Annual Meeting") on April 20, 2016. SHAREHOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE ANNUAL MEETING THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE ANNUAL MEETING. Shareholders are able to obtain a free copy of that definitive proxy statement and other materials that the Company filed with the SEC at the SEC's website at www.sec.gov. That definitive proxy statement and these other materials will also be available free of charge by directing a request to Harris & Harris Group, Inc., Attn: Investor Relations, 1450 Broadway, 24th Floor, New York, NY 10018, or from the Company at www.hhvc.com.
The Company, its directors and its named executive officers may be deemed to be participants in the solicitation of proxies from the Company's shareholders in connection with the Annual Meeting. Shareholders may obtain information regarding the names, affiliations and interests of such individuals in the Company's proxy statement filed on April 20, 2016, for the 2016 Annual Meeting of Shareholders. To the extent that holdings of the Company's securities on the part of those individuals have changed since the date of that proxy statement, those changes have been reflected on Statements of Changes in Ownership on Forms 3 or 4 filed with the Securities and Exchange Commission. More current information regarding the interests of the directors and named executive officers of Harris & Harris Group will be contained in the definitive proxy statement referred to in the preceding paragraph.
Forward-Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references and links to the websites www.HHVC.com, www.dwavesys.com, www.hzo.com, www.metabolon.com, www.orig3n.com, www.sec.gov and www.facebook.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
For more information, please click here
Copyright © Harris & Harris Group
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Hardware
The present and future of computing get a boost from new research July 21st, 2023
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Quantum Computing
New quantum encoding methods slash circuit complexity in machine learning November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Researchers observe “locked” electron pairs in a superconductor cuprate August 16th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||